Oscotec Inc.
KOSDAQ 039200.KQ
Oscotec Inc. Shareholders' Equity for the year ending December 31, 2023: USD 75.97 M
-
Oscotec Inc. Shareholders' Equity for the year ending December 31, 2022 was USD 96.78 M, a 301.11% change year over year.
-
Oscotec Inc. Shareholders' Equity for the year ending December 31, 2021 was USD 24.13 M, a -50.45% change year over year.
-
Oscotec Inc. Shareholders' Equity for the year ending December 31, 2020 was USD 48.70 M, a 10.15% change year over year.
-
Oscotec Inc. Shareholders' Equity for the year ending December 31, 2019 was USD 44.21 M, a 6.83% change year over year.
| Date | Shareholders' Equity | Minority Interest | Total Equity | Total Stockholders Equity and Liabilities |
|---|
| CEO | Sung-Hee Son |
| IPO Date | Jan. 17, 2007 |
| Location | South Korea |
| Headquarters | A Building, Korea Bio Park |
| Employees | 50 |
| Sector | Health Care |
| Industries | |
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.
Past 5 years
USD 89.21
USD 108.37
USD 3.70
StockViz Staff
January 15, 2025
Any question? Send us an email